OMACETAXINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12[C@H](O)C(OC)=C[C@@]13CCCN3CCC4=CC5=C(OCO5)C=C24

InChI

InChIKey=YMNCVRSYJBNGLD-KURKYZTESA-N

InChI=1S/C18H21NO4/c1-21-15-9-18-4-2-5-19(18)6-3-11-7-13-14(23-10-22-13)8-12(11)16(18)17(15)20/h7-9,16-17,20H,2-6,10H2,1H3/t16-,17-,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23053254http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23790799

Omacetaxine mepesuccinate (trade name Synribo) formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). It is a natural ester of the alkaloid cephalotaxine from Cephalotaxus harringtonia, now manufactured by hemi-synthesis. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of wild-type and T315I mutated Bcr-Abl CML.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
60S ribosomal protein L3 3 Target ID: P39023 Gene ID: 6122.0 Gene Symbol: RPL3 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Chronic myeloid leukemia, chronic phase 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Primary	Approved 8429	SYNRIBO Approved Use Indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate.There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO Launch Date 2012
Chronic myeloid leukemia, accelerated phase 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Primary	Approved 8429	SYNRIBO Approved Use Indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate.There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO Launch Date 2012
Unknown 2578

C_max

Value	Dose	Co-administered	Analyte	Population
25.1 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23053254	1.25 mg/m² single, subcutaneous dose: 1.25 mg/m² route of administration: Subcutaneous experiment type: SINGLE co-administered:		[NO STEREO] OMACETAXINE MEPESUCCINATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
136.2 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23053254	1.25 mg/m² single, subcutaneous dose: 1.25 mg/m² route of administration: Subcutaneous experiment type: SINGLE co-administered:		[NO STEREO] OMACETAXINE MEPESUCCINATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.96 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23053254	1.25 mg/m² single, subcutaneous dose: 1.25 mg/m² route of administration: Subcutaneous experiment type: SINGLE co-administered:		[NO STEREO] OMACETAXINE MEPESUCCINATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 mg/m2 1 times / day multiple, subcutaneous MTD Dose: 5 mg/m2, 1 times / day Route: subcutaneous Route: multiple Dose: 5 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16847470	unhealthy, 57 years (range: 20–79 years) n = 12 Health Status: unhealthy Condition: Chronic Myeloid Leukemia Age Group: 57 years (range: 20–79 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/16847470	DLT: Haematemesis, Pulmonary aspergillosis... Other AEs: Anasarca... Dose limiting toxicities: Haematemesis (grade 3, 1 patient) Pulmonary aspergillosis (grade 4, 1 patient) Skin rash (grade 3, 1 patient) Scalp pain (grade 3, 1 patient) Other AEs: Anasarca (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16847470
3 mg/m2 1 times / day multiple, subcutaneous Dose: 3 mg/m2, 1 times / day Route: subcutaneous Route: multiple Dose: 3 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16847470	unhealthy, 57 years (range: 20–79 years) n = 12 Health Status: unhealthy Condition: Chronic Myeloid Leukemia Age Group: 57 years (range: 20–79 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/16847470	DLT: Hyperglycaemia, Diabetic hyperosmolar coma... Dose limiting toxicities: Hyperglycaemia (grade 3, 1 patient) Diabetic hyperosmolar coma Sources: https://pubmed.ncbi.nlm.nih.gov/16847470
1.25 mg/m2 2 times / day multiple, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: multiple Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	unhealthy, 59 years n = 108 Health Status: unhealthy Condition: chronic phase chronic myeloid leukemia Age Group: 59 years Sex: M+F Population Size: 108 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Disc. AE: Thrombocytopenia, Alanine aminotransferase increased... Other AEs: Thrombocytopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (2%) Alanine aminotransferase increased (2%) Other AEs: Thrombocytopenia (all grades, 74%) Thrombocytopenia (grade 3-4, 67%) Anemia (all grades, 61%) Anemia (grade 3-4, 36%) Neutropenia (all grades, 50%) Neutropenia (grade 3-4, 45%) Lymphopenia (all grades, 17%) Lymphopenia (grade 3-4, 16%) Bone marrow failure (all grades, 10%) Bone marrow failure (grade 3-4, 10%) Febrile neutropenia (all grades, 10%) Febrile neutropenia (grade 3-4, 10%) Diarrhea (all grades, 42%) Diarrhea (grade 3-4, 1%) Nausea (all grades, 32%) Nausea (grade 3-4, 1%) Constipation (grade 1-2, 15%) Abdominal pain upper (grade 1-2, 14%) Vomiting (grade 1-2, 12%) Fatigue (all grades, 26%) Fatigue (grade 3-4, 5%) Pyrexia (all grades, 24%) Pyrexia (grade 3-4, 1%) Asthenia (all grades, 23%) Asthenia (grade 3-4, 1%) Edema peripheral (grade 1-2, 13%) Infusion site reactions (grade 1-2, 34%) Arthralgia (all grades, 19%) Arthralgia (grade 3-4, 1%) Pain in extremity (all grades, 13%) Pain in extremity (grade 3-4, 1%) Back pain (all grades, 11%) Back pain (grade 3-4, 2%) Headache (all grades, 19%) Headache (grade 3-4, 1%) Insomnia (grade 1-2, 10%) Cough (all grades, 16%) Cough (grade 3-4, 1%) Epistaxis (all grades, 15%) Epistaxis (grade 3-4, 1%) Alopecia (grade 1-2, 15%) Rash (grade 1-2, 10%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day multiple, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: multiple Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57	unhealthy, 59 years n = 158 Health Status: unhealthy Condition: chronic phase, Accelerated Phase chronic myeloid leukemia Age Group: 59 years Sex: M+F Population Size: 158 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57	Disc. AE: Bone marrow failure, Sepsis... AEs leading to discontinuation/dose reduction: Bone marrow failure (1%) Sepsis (1%) Multiorgan failure (1%) Gout (1%) Renal failure (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57
1.25 mg/m2 2 times / day multiple, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: multiple Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	unhealthy, 59 years n = 55 Health Status: unhealthy Condition: Chronic Myeloid Leukemia – Accelerated Phase Age Group: 59 years Population Size: 55 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Other AEs: Anemia, Anemia... Other AEs: Anemia (all grades, 51%) Anemia (grade 3-4, 36%) Febrile neutropenia (all grades, 20%) Febrile neutropenia (grade 3-4, 16%) Neutropenia (all grades, 20%) Neutropenia (grade 3-4, 18%) Thrombocytopenia (all grades, 56%) Thrombocytopenia (grade 3-4, 49%) Diarrhea (all grades, 35%) Diarrhea (grade 3-4, 7%) Nausea (all grades, 27%) Nausea (grade 3-4, 4%) Vomiting (all grades, 15%) Vomiting (grade 3-4, 2%) Abdominal pain (grade 1-2, 13%) Fatigue (all grades, 31%) Fatigue (grade 3-4, 9%) Pyrexia (all grades, 29%) Pyrexia (grade 3-4, 2%) Asthenia (all grades, 24%) Asthenia (grade 3-4, 2%) Chills (grade 1-2, 13%) Infusion site reactions (grade 1-2, 22%) Anorexia (all grades, 13%) Anorexia (grade 3-4, 2%) Pain in extremity (all grades, 11%) Pain in extremity (grade 3-4, 2%) Headache (grade 1-2, 13%) Cough (grade 1-2, 15%) Dyspnea (all grades, 11%) Dyspnea (grade 3-4, 2%) Epistaxis (all grades, 11%) Epistaxis (grade 3-4, 2%) Bacterial infection (all grades, 56%) Bacterial infection (grade 3-4, 20%) Infection viral (all grades, 56%) Infection viral (grade 3-4, 20%) Fungal infection (all grades, 56%) Fungal infection (grade 3-4, 20%) Infection NOS (all grades, 56%) Infection NOS (grade 3-4, 20%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: steady Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	unhealthy, 59 years n = 108 Health Status: unhealthy Condition: chronic phase chronic myeloid leukemia Age Group: 59 years Sex: M+F Population Size: 108 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Disc. AE: Pancytopenia... AEs leading to discontinuation/dose reduction: Pancytopenia (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: steady Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	unhealthy, 59 years n = 108 Health Status: unhealthy Condition: chronic phase CML Age Group: 59 years Sex: M+F Population Size: 108 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Disc. AE: Alanine aminotransferase increased... AEs leading to discontinuation/dose reduction: Alanine aminotransferase increased (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous Recommended Dose: 1.25 mg/m2, 2 times / day Route: subcutaneous Route: steady Dose: 1.25 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57	unhealthy, 59 years n = 108 Health Status: unhealthy Condition: chronic phase CML Age Group: 59 years Sex: M+F Population Size: 108 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57	Disc. AE: Tachyarrhythmia, Diplopia... AEs leading to discontinuation/dose reduction: Tachyarrhythmia (1%) Diplopia (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 57
8 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 8 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 8 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6478448	unhealthy Health Status: unhealthy Condition: refractory malignancies Sources: https://pubmed.ncbi.nlm.nih.gov/6478448	DLT: Hypotension... Dose limiting toxicities: Hypotension Sources: https://pubmed.ncbi.nlm.nih.gov/6478448
2.5 mg/m2 2 times / day multiple, subcutaneous Overdose Dose: 2.5 mg/m2, 2 times / day Route: subcutaneous Route: multiple Dose: 2.5 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	unhealthy n = 1 Health Status: unhealthy Condition: Chronic Myeloid Leukemia Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Disc. AE: Gastrointestinal disorders, Gingival hemorrhage... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (1 patient) Gingival hemorrhage (1 patient) Alopecia (1 patient) Thrombocytopenia (grade 4, 1 patient) Neutropenia (grade 4, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
2.5 mg/m2 2 times / day multiple, subcutaneous Overdose Dose: 2.5 mg/m2, 2 times / day Route: subcutaneous Route: multiple Dose: 2.5 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 67	unhealthy n = 1 Health Status: unhealthy Condition: CML Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 67	Disc. AE: Gingival hemorrhage, Gastrointestinal disorders... AEs leading to discontinuation/dose reduction: Gingival hemorrhage (1 patient) Gastrointestinal disorders (1 patient) Alopecia (1 patient) Thrombocytopenia (grade 4, 1 patient) Neutropenia (grade 4, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf Page: p. 67

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587		inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A 72 CYP2C19 1478 P-gp 1461	CYP 270 P-gp 1537	CYP1A 56

Drug as perpetrator

Target	Modality	Activity	Metabolite
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000ClinPharmR.pdf#page=20 Page: 20.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=61 Page: 61,56	strong [Inhibition 10 uM]
CYP1A 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=61 Page: 61,56	weak [Inhibition 10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=61 Page: 61,56	weak [Inhibition 10 uM]	DMHHT 3
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=61 Page: 61,56	weak [Inhibition 10 uM]
CYP1A 121	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=61 Page: 61.0	weak

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=54 Page: 54.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000ClinPharmR.pdf#page=20 Page: 20.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000PharmRedt.pdf#page=43 Page: 43.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00BBK4	https://www.aablocks.com/goods/Goods/detail?id=AA00BBK4
AHH Chemical co.,ltd	NP-0431	http://www.ahhchemical.com/product/NP-0431.html
Aaron Chemicals	AR00BCBW	http://www.aaronchem.com/24316-19-6
AbMole Bioscience	M3942	http://www.abmole.com/products/cephalotaxine.html
Achemtek	0104-028087	http://www.achemtek.com/24316-19-6
Acorn PharmaTech	ACN-035228	http://www.acornpharmatech.com/
Ambeed	A863555	https://www.ambeed.com/products/24316-19-6.html
Angene	AGN-PC-0R05OB	http://www.angenechemical.com/productshow/AGN-PC-0R05OB.html
Aurum Pharmatech LLC	S-7655	http://www.Aurumpharmatech.com/Product/ProductDetails/S_7655
AvaChem Scientific	3156	http://www.avachem.com/productSearch.asp?3156
BLD Pharm	BD16925	http://www.bldpharm.com/products/24316-19-6.html
CSNpharm	CSN12450	https://www.csnpharm.com/products/cephalotaxine.html
Chem Scene	CS-3006	http://www.chemscene.com/24316-19-6.html
ChemFaces	CFN90919	http://www.chemfaces.com/natural/Cephalotaxine-CFN90919.html
Chemspace	CSSB00000036076	https://chem-space.com/CSSB00000036076
DC Chemicals	DC9649	http://www.dcchemicals.com/product_show-Cephalotaxlen.html
Hairui	HR120093	http://www.hairuichem.com/en/product/24316-19-6.html
Lab Network	LN00176704	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00176704
Matrix Scientific	76038	https://www.matrixscientific.com/076038.html
MedChem Express	HY-N0838	https://www.medchemexpress.com/cephalotaxlen.html
MuseChem	I002813	https://www.musechem.com/product/I002813.html
Oakwood	79392	http://www.oakwoodchemical.com/p-73475-079392.aspx
Smolecule	S523194	http://www.smolecule.com/products/s523194
Smolecule	S749414	https://www.smolecule.com/products/s749414
THE BioTek	bt-263600	https://www.thebiotek.com/product/inhibitors/bt-263600
abcr GmbH	AB479786	http://www.abcr.com/shop/en/AB479786
eNovation Chemicals	D574859	http://www.enovationchem.com/productDetails.asp?productID=D574859
eNovation Chemicals	D628756	https://www.enovationchem.com/ProductDetails.asp?ProductID=D628756
eNovation Chemicals	D679660	https://www.enovationchem.com/ProductDetails.asp?ProductID=D679660

PubMed

Title	Date	PubMed
Inhibition of protein synthesis in intact HeLa cells.	1975 Oct	1190754
Inhibition of translation in eukaryotic systems by harringtonine.	1977 Jan	319998
Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.	2001 Apr	11368358
A formal total synthesis of (+/-)-cephalotaxine using sequential N-acyliminium ion reactions.	2002 Mar 21	11893177
Altering chemosensitivity by modulating translation elongation.	2009	19412536
[Expression and function of Ahi-1 gene in Jurkat cells].	2009 Apr	19379585

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 20:11:19 GMT 2023` Edited by `admin` on `Fri Dec 15 20:11:19 GMT 2023`
Record UNII	84MI6OYN4Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OMACETAXINE

Common Name

English

Cephalotaxine [WHO-DD]

Common Name

English

OMACETAXINE [VANDF]

Common Name

English

NSC-128487

Code

English

(-)-CEPHALOTAXINE

Common Name

English

Omacetaxine [WHO-DD]

Common Name

English

NSC-245454

Code

English

CEPHALOTAXINE

Common Name

English

CEPHALOTAXINE [MI]

Common Name

English

(1S-(1.ALPHA.,3AS*,14B.BETA.))-1,5,6,8,9,14B-HEXAHYDRO-2-METHOXY-4H-CYCLOPENTA(A)(1,3)DIOXOLO(4,5-H)PYRROLO(2,1-B)(3)BENZAZEPIN-1-OL

Common Name

English

Classification Tree Code System Code

LIVERTOX

NBK548034